Keros Therapeutics (KROS) EPS (Weighted Average and Diluted) (2020 - 2025)
Keros Therapeutics posted quarterly EPS (Weighted Average and Diluted) of -$0.38 for Q4 2025, up 66.07% year-on-year from -$0.23 in Q4 2024, and down 111.11% on a QoQ basis from -$0.18 in Q3 2025.
Keros Therapeutics (KROS) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.38 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 66.07% year-over-year to -$0.38; the trailing twelve-month figure through Dec 2025 stood at $2.3 (up 146.09% YoY), and the FY2025 full-year result was $2.3, up 146.0% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at -$0.38, down from -$0.18 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $3.62 in Q1 2025 and bottomed at -$1.41 in Q3 2024.
- The 5-year median for EPS (Weighted Average and Diluted) is -$1.06 (2022), against an average of -$0.73.
- The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) sank 266.67%; it then surged 399.17% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.3 in 2021, then tumbled by 266.67% to -$1.1 in 2022, then slipped by 21.82% to -$1.34 in 2023, then increased by 16.42% to -$1.12 in 2024, then jumped by 66.07% to -$0.38 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.38 (Q4 2025), -$0.18 (Q3 2025), and -$0.76 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -0.38 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.38 |
| Sep 30, 2025 | -0.18 |
| Jun 30, 2025 | -0.76 |
| Mar 31, 2025 | 3.62 |
| Dec 31, 2024 | -1.12 |
| Sep 30, 2024 | -1.41 |
| Jun 30, 2024 | -1.25 |
| Mar 31, 2024 | -1.21 |
| Dec 31, 2023 | -1.34 |
| Sep 30, 2023 | -1.33 |
| Jun 30, 2023 | -1.27 |
| Mar 31, 2023 | -1.26 |
| Dec 31, 2022 | -1.10 |
| Sep 30, 2022 | -0.92 |
| Jun 30, 2022 | -1.13 |
| Mar 31, 2022 | -1.01 |
| Dec 31, 2021 | -0.30 |
| Sep 30, 2021 | -0.87 |
| Jun 30, 2021 | -0.67 |
| Mar 31, 2021 | -0.68 |
| Dec 31, 2020 | -0.28 |
| Sep 30, 2020 | -0.60 |
| Jun 30, 2020 | -0.62 |